Skip to search formSkip to main contentSkip to account menu

fingolimod Oral Capsule [Gilenya]

National Institutes of Health

Related topics

Related topics

3 relations
GilenyaOral Capsule

Narrower (1)

fingolimod 0.5 MG Oral Capsule [Gilenya]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
2018
2018
Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis
The introduction of oral disease modifying therapies has transformed the treatment landscape for patients with multiple sclerosis… 
2018
2018
Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency
BackgroundCongenital sphingosine-1-phosphate (S1P) lyase deficiency due to biallelic mutations in SGPL1 gene has recently been… 
2017
2017
Fingolimod (Gilenya®) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L‐type calcium channel?
Cardiac arrhythmias and ECG abnormalities including bradycardia, prolongation of the QT interval, and atrioventricular (AV… 
2016
2016
Repurposing Tecfidera for cancer
The compound dimethyl fumarate (DMF) has been an approved drug in Europe for several decades as a therapeutic for psoriasis and… 
2014
2014
Utilidad de los registros electrónicos de medicamentos:: registro español de pacientes tratados con fingolimod (Gilenya ®)
Introduccion. Se describe el diseno de un registro electronico de los pacientes con esclerosis multiple que inician tratamiento… 
Review
2012
Review
2012
Endogeneous remyelination: findings in human studies.
In multiple sclerosis, conduction block in demyelinated axons underlies early neurological symptoms, whereas axonal transection… 
2012
2012
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis
Sphingosine 1-phosphate (S1P), a lysophospholipid mediator, is generated from sphingosine by sphingosine kinases and binds five… 
2012
2012
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands
Abstract Objective: To assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri… 
2012
2012
Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya(R)) in Multiple Sclerosis Patients in Germany…
Objective: In order to investigate the safety and efficacy of fingolimod (Gilenya®) in everyday clinical practice, a 4000-patient… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)